Intercontinental Exchange Inc. Common Stock vs Twist Bioscience Corp — how do they compare? Intercontinental Exchange Inc. Common Stock trades at $156.51 (market cap $87.21B), while Twist Bioscience Corp trades at $160 (market cap $10.08B). The key difference: Intercontinental Exchange Inc. Common Stock is far larger — about 8.7× Twist Bioscience Corp's market cap, and Intercontinental Exchange Inc. Common Stock pays a 1.34% dividend while Twist Bioscience Corp pays none. Which is the better fit depends on your goals.
| ICE | TWST | |
|---|---|---|
Market Cap | $87.21B | $10.08B |
Volume | 2,029,112 | 4,229,037 |
Sector | Financials | Health |
52-Week High | $175.10 | $205.00 |
52-Week Low | $122.91 | $25.45 |
Enterprise Value | $105.12B | $10.01B |
Dividend Yield | 1.34% | — |
Typical Hold Time | — | 27 Days |
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
TWST trades at $155.65, down 6.78% over 24 hours, with a bearish technical signal and negative cash flows. Revenue growth is strong, reaching $377M in 2025, but the company remains unprofitable with a net income margin of -31.66%. Recent news highlights its role in Eli Lilly's AI-driven drug discovery platform, boosting sentiment despite earnings misses.
The outlook is mixed: analyst consensus is bullish with a $145.20 price target, but high valuation multiples and persistent losses pose risks. Investment opportunity hinges on AI partnerships driving future profitability, while execution risks and cash burn require careful monitoring.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
Latest headlines on both assets
Intercontinental Exchange provides technology and data services for financial institutions, corporations, and governments. Its businesses include exchanges and clearing, fixed-income data and analytics, and mortgage technology.
Read more on ICE →Twist Bioscience Corp is a synthetic biology company. It develops a disruptive DNA synthesis platform to industrialize the engineering of biology. The company's DNA synthesis platform utilizes a proprietary semiconductor-based synthetic DNA manufacturing process that synthesizes DNA on silicon instead of on traditional well plastic plates to enable the production of high-quality synthetic DNA faster and affordable as well as overcomes inefficiencies. Powering cost-effective, rapid high-throughput synthesis, it enables researchers to rapidly realize opportunities ahead. Geographically, it derives a majority of revenue from the United States.
Read more on TWST →